Ginkgo biloba special extract LI 1370 improves dual-task walking in patients with MCI: a randomised, double-blind, placebo-controlled exploratory study

Gschwind, Yves J.; Bridenbaugh, Stephanie A.; Reinhard, Sarah M.; Granacher, Urs; Monsch, Andreas U.; Kressig, Reto W.

doi:10.1007/s40520-016-0699-y

Cited by 22 publications

(30 citation statements)

References 60 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of these, 7 tested medication, and 1 tested a medical device. All antidementia medication studies were non‐RCTs; the study on ginkgo biloba extract and the study on the medical device were RCTs. Sample sizes ranged from 14 to 120 and mean age from 67.8 to 85.4, and all the studies included a majority of female participants (range 52.9–88.9%).…”

Section: Resultsmentioning

confidence: 99%

Interventions to Improve Gait in Older Adults with Cognitive Impairment: A Systematic Review

Zhang

Low

Gwynn

et al. 2018

J American Geriatrics Society

View full text Add to dashboard Cite

Objectives To review intervention programs that measure gait to investigate what features of the intervention may contribute to improving gait in older adults with cognitive impairment or dementia. Design Systematic review using Medline, Cinahl, Scopus, PsychInfo, Amed, Embase, Web of Science, and PubMed for original research published in English between January 1, 2000, and July 23, 2018, to identify interventional controlled trials. Narrative synthesis was undertaken. Results Of 6,379 citations, 36 articles met inclusion criteria. Interventions were categorized as medication or medical devices (8 studies), exercise (19 studies), and exercise plus cognitive training (9 studies). Antidementia medication may improve gait variability in people with Alzheimer's disease. Exercise programs focusing on strength and balance training, especially when combined with functional mobility training, improve gait in people with mild cognitive impairment or dementia. Exercise plus cognitive training programs combining strength and balance training, functional mobility training, and training on attention and executive function also improve gait. Conlusion Physical and cognitive factors affect gait performance, and both should be addressed in intervention programs. Physical exercises including functional mobility training, especially walking, have better results than physical programs with only static, resistance, and flexibility training. Cognitive intervention should be concomitant with physical exercises rather than separate, with a focus on attention and executive function. Combining physical training with cognitive training in a functional context may assist older adults with cognitive impairment generalize from training to everyday activity. J Am Geriatr Soc 67:381–391, 2019.

show abstract

Section: Resultsmentioning

confidence: 99%

Interventions to Improve Gait in Older Adults with Cognitive Impairment: A Systematic Review

Zhang

Low

Gwynn

et al. 2018

J American Geriatrics Society

View full text Add to dashboard Cite

show abstract

“…In addition to cognitive deficits, patients with MCI can experience motor dysfunction, including deficits in gait and balance (Verghese et al 2002). Gschwind et al investigated the efficacy of a GBE to improve gait stability (Gschwind et al 2017). This GBE (120 mg) administered twice daily in MCI patients aged 50-85 years improved dual-task-related gait performance in MCI patients (Gschwind et al 2017).…”

Section: Pharmacological Interventionsmentioning

confidence: 99%

“…Gschwind et al investigated the efficacy of a GBE to improve gait stability (Gschwind et al 2017). This GBE (120 mg) administered twice daily in MCI patients aged 50-85 years improved dual-task-related gait performance in MCI patients (Gschwind et al 2017).…”

Section: Pharmacological Interventionsmentioning

confidence: 99%

Management of mild cognitive impairment (MCI): The need for national and international guidelines

Kasper

Bancher

Eckert

et al. 2020

The World Journal of Biological Psychiatry

Self Cite

111

View full text Add to dashboard Cite

Objectives: To review available evidence of pharmacological and non-pharmacological treatment for MCI and analyse information and limitations in national and international guidelines. Methods: Experts from several European countries conducted a qualitative review of the literature on MCI and treatments for MCI, as well as respective chapters in national and international guidelines on dementia/MCI. Psychotherapeutic/psychosocial treatments were excluded from the review. Results: Consensus diagnostic criteria for MCI are available, making early recognition and accurate classification of MCI subtypes possible. MCI can be identified in a primary care setting. Further corroboration and differential diagnosis should be done at specialist level. Mixed pathologies are the rule in MCI, thus a multi-target treatment approach is a rational strategy. Promising evidence has been generated for multi-domain interventions. Limited evidence is available for different pharmacological classes that have been investigated in MCI clinical trials (e.g. acetylcholinesterase inhibitors). EGb 761 V R improved symptoms in some clinical trials; it is the only pharmacological treatment recommended in existing guidelines for the symptomatic treatment of MCI. Conclusions: MCI is recognised as an important treatment target and some recent national guidelines have considered symptomatic treatment recommendations for MCI. However, more needs to be done, especially at an international level.

show abstract

“…For instance, a cognitive and gait dual‐tasking assessment in early Alzheimer's disease can provide derived digital outcomes that may distinguish amyloid‐positive from amyloid‐negative elderly subjects and predict falls . This paradigm has also been used to measure treatment effects of Ginkgo biloba in mild cognitive impairment (MCI) . In general, digital endpoints and diagnostics should be rater‐independent, more accurate, and more reliable than pen‐and‐paper COAs.…”

Section: Digital Technologies In Clinical Researchmentioning

confidence: 99%

Digital Therapeutics: An Integral Component of Digital Innovation in Drug Development

Sverdlov¹,

Dam

Hannesdóttir

et al. 2018

Clin Pharma and Therapeutics

104

View full text Add to dashboard Cite

Digital therapeutics represent a new treatment modality in which digital systems such as smartphone apps are used as regulatory-approved, prescribed therapeutic interventions to treat medical conditions. In this article we provide a critical overview of the rationale for investing in such novel modalities, including the unmet medical needs addressed by digital therapeutics and the potential for reducing current costs of medical care. We also discuss emerging pathways to regulatory approval and how innovative business models are enabling further growth in the development of digital therapeutics. We conclude by providing some recent examples of digital therapeutics that have gained regulatory approval and highlight opportunities for the near future.

show abstract

Ginkgo biloba special extract LI 1370 improves dual-task walking in patients with MCI: a randomised, double-blind, placebo-controlled exploratory study

Cited by 22 publications

References 60 publications

Interventions to Improve Gait in Older Adults with Cognitive Impairment: A Systematic Review

Interventions to Improve Gait in Older Adults with Cognitive Impairment: A Systematic Review

Management of mild cognitive impairment (MCI): The need for national and international guidelines

Digital Therapeutics: An Integral Component of Digital Innovation in Drug Development

Contact Info

Product

Resources

About